companies & Investments

A track record of innovation
Accelerating mental healthcare solutions

A track record of innovation
Accelerating mental healthcare solutions

ATAI Life Sciences is dedicated to bringing innovation to mental healthcare, a field that has seen little progress since the development of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in the 1980s and 1990s, respectively.

Want to learn more about our companies and investments?  Check them out below.

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.
compasspathways.com

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

DemeRx

developing ibogaine and noribogaine for the treatment of opioid use disorders
demerx.com

Innoplexus

leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
innoplexus.com

GABA Therapeutics

develops GRX-917 — a deuterated version of etifoxine — for anxiety.
gabarx.com

EntheogeniX Biosciences

leverages the power of AI and computational biophysics to design the next generation of mental health drugs
entheogenixbio.com

Neuronasal

preventing post-concussion injury and mental health complications by novel nose-to-brain drug delivery of NAC
neuronasal.com

Introspect DTx

developing personalized digital tools to enhance psychedelics-assisted psychotherapy
introspectme.com

Kures

developing novel therapeutics for addiction and depression
kures.life

Viridia Life Sciences

exploring the potential of rapid acting psychedelics for scalable mental healthcare
viridia.life

EmpathBio

leveraging the power of MDMA to deliver next generation PTSD treatments
empath.bio